Navigation Links
Circassia Initiates Further Phase II Clinical Study of Toleromune(R) Anti-Allergy Technology
Date:10/2/2008

OXFORD, England, October 2 /PRNewswire/ -- Circassia Ltd, a specialty biopharmaceutical company focused on the fields of allergy and critical care, today announced the start of a further phase II clinical study of its ToleroMune(R) technology in the field of cat allergy. The trial builds on positive results achieved in an earlier phase II study, which demonstrated the potential clinical benefits of the ToleroMune approach to allergy desensitization.

In the previous phase II clinical trial, patients experienced substantially reduced reactions to cat allergens after a single administration of ToleroMune therapy. The current study builds on this work, and will explore different 4-dose treatment regimens, which are designed to enhance the patients' response and determine the best therapeutic approach. During the study, patients will receive a controlled dose of cat allergen in an environmental exposure chamber both before and after treatment, and will then complete a questionnaire to score their allergic rhinitis symptoms. This will allow investigators to evaluate the impact of the different treatment regimes. The double-blind, randomized, placebo-controlled trial will include a total of 120 volunteers with confirmed cat allergies. The study, which is already underway in Canada, is progressing well with approximately 20% of patients enrolled for screening so far.

"This study is of great importance for Circassia as it is designed to define the most effective treatment regime for our ToleroMune allergy products, and in particular for the phase III studies of our cat-allergy therapy that are planned to begin in the second half of 2009," said Steve Harris, Circassia's CEO. "The results of our trials to date show that our ToleroMune approach offers patients substantial potential benefits. Conventional allergy treatments either address symptoms only or require many doses over a period of months under specialist supervision because they can result in serio
'/>"/>

SOURCE Circassia Ltd
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Circassia Achieves Successful Phase II Clinical Results With Toleromune(R) Anti-Allergy Technology
2. Baxter Initiates Phase III Trial for the Treatment of Alzheimers Disease
3. S*BIO Initiates U.S. Phase I Clinical Trials of Oral JAK2 Inhibitor SB1518 for the Treatment of Hematological Malignancies
4. Enanta Initiates Phase 1 Study on EDP-322, an Oral Antibiotic With Activity Against Hospital- and Community-Acquired MRSA
5. QuatRx Initiates Second Phase 3 Study of Ophena(TM) (Ospemifene Tablets) in Women With Postmenopausal Vaginal Syndrome
6. Cystic Fibrosis Axentis Pharma Initiates Clinical Trial for Lung Infections
7. Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS)
8. Healthpoint Initiates Randomized, Double-Blind Study to Evaluate Effectiveness of Collagenase SANTYL(R) Ointment on Wound Healing
9. Enobia Pharma Initiates Clinical Testing of Enzyme Replacement Therapy to Treat Hypophosphatasia
10. Isis Initiates Clinical Trial of CRP Drug
11. Tolerx Initiates Dosing of Otelixizumab, a Novel Type 1 Diabetes Agent, in DEFEND, a Phase 3 Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... July 31, 2014  Alexza Pharmaceuticals, Inc. (Nasdaq: ... on its pipeline and new product development efforts. In ... initiate a Phase 2a study of AZ-002 (Staccato ... the management of patients with acute repetitive seizures. ... -based product candidates for development - AZ-008 and ...
(Date:7/31/2014)... -- UBM Medica US announces that Cancer Network ... exclusive slide shows dealing with communication in the oncology ... Cancer Network, the online home ... and podcasts about the latest clinical findings. Among the ... , End-of-life care is challenging for even the most ...
(Date:7/31/2014)... 31, 2014  Decision Resources Group,s experts ... by the Affordable Care Act (ACA), which ... pharmaceutical therapies. The ACA altered how Managed ... regulations and expanded access via government-supported programs. ... exchanges—state-based marketplaces set up by states or ...
Breaking Medicine Technology:Alexza Provides Pipeline Update 2Alexza Provides Pipeline Update 3Alexza Provides Pipeline Update 4Alexza Provides Pipeline Update 5Alexza Provides Pipeline Update 6Cancer Network Highlights Methods Oncologists Can Use to Improve Communication 2Cancer Network Highlights Methods Oncologists Can Use to Improve Communication 3Health Exchanges Drive Change In MCO Strategies And Physician Prescribing Decisions; Impact On Pharma Mixed 2Health Exchanges Drive Change In MCO Strategies And Physician Prescribing Decisions; Impact On Pharma Mixed 3Health Exchanges Drive Change In MCO Strategies And Physician Prescribing Decisions; Impact On Pharma Mixed 4
... Untold Numbers of Consumers Still Left Disabled By Its ... GlaxoSmithKline, the maker of popular denture adhesives Poligrip and Super ... its denture adhesive products.  The pharmaceutical giant has added the potentially ... consuming large quantities of zinc over an extended period of time ...
... , , SHANGHAI , ... WX ), a leading pharmaceutical, biotechnology and medical device R&D outsourcing ... announced that it will release financial results for the fourth quarter of ... 8, 2010 (which will be Tuesday morning, March 9, 2010 ...
Cached Medicine Technology:Leading Denture Cream Litigation Firm Welcomes GSK Announcement of Removal of Zinc From Its Denture Creams 2Leading Denture Cream Litigation Firm Welcomes GSK Announcement of Removal of Zinc From Its Denture Creams 3WuXi PharmaTech Schedules Fourth-Quarter 2009 Earnings Release 2WuXi PharmaTech Schedules Fourth-Quarter 2009 Earnings Release 3
(Date:8/1/2014)... at the University of California, San Diego School of ... in chili peppers produces chronic activation of a ... a reaction that ultimately reduces the risk of colorectal ... 1, 2014 issue of The Journal of Clinical ... TRPV1, was originally discovered in sensory neurons, where it ...
(Date:8/1/2014)... in regulating appetite and whole-body metabolism. A protein known ... food intake and body weight, but the identity of ... A new study in the Journal of ... type of neuron known as pro-opiomelanocortin (POMC) neurons is ... Sabrina Diano and colleagues at Yale University School of ...
(Date:8/1/2014)... Barbara Bronson Gray HealthDay Reporter ... obese and work in manufacturing jobs may have significantly less endurance ... a study of 32 people -- half were obese, half were ... times that were about 60 percent longer. Obesity also was ... Being older -- 50 to 65 years of ...
(Date:8/1/2014)... 1, 2014 (HealthDay News) -- The U.S. Food and ... new drug, Jardiance, to help fight type 2 diabetes. ... added to existing treatment regimens to control blood sugar ... Rosebraugh, director of the Office of Drug Evaluation II ... said in an agency statement. The FDA also ...
(Date:8/1/2014)... study, researchers at University Hospitals Rainbow Babies & Children,s ... at greater risk for death on a commercial airline ... worldwide between January 2010 and June 2013 and found ... age of 2. , The study was conducted ... of an in-flight pediatric fatality onboard commercial airline flights ...
Breaking Medicine News(10 mins):Health News:Pepper and halt: Spicy chemical may inhibit gut tumors 2Health News:Obesity Might Slow You Down at Work 2Health News:Obesity Might Slow You Down at Work 3Health News:FDA Approves New Type 2 Diabetes Drug 2Health News:New research characterizes in-flight pediatric deaths 2
... and areas for improvement in reform proposals for small businesses ... on Small Business and Entrepreneurship Chair Mary Landrieu, D-La., and ... to better understand the needs of small businesses in health ... those needs. , "We are here today to discuss one ...
... , WASHINGTON, Oct. 20 Speaker Nancy Pelosi, House ... Michigan held a press availability this afternoon ... the urgency of health insurance reform for children with pre-existing ... and Jessica Segal of Texas told ...
... benefits patients, study shows , TUESDAY, Oct. 20 (HealthDay ... patients when used up to 4.5 hours after a ... provide further evidence to increase the tPA treatment window ... Previously published findings from the ECASS III study indicated ...
... 20 (HealthDay News) -- In an effort to reduce ... Reproductive Medicine has revised its recommendations on the number ... fertilization procedures. , The society reports that the ... For one, it says that doctors should only use ...
... Body Worlds 2 & The Brain ... October 17, and will be one of many points of ... of scientific treasures. The second-largest medical research and education center ... medical, anatomical and scientific sites--from the nation,s first hospital and ...
... patients in U.S. hospitals fail to get recommended therapy, ... A recommended treatment for heart failure is underused in ... of aldosterone antagonist therapy in patients with heart failure ... failure guidelines established by the American College of ...
Cached Medicine News:Health News:Landrieu, Snowe Champion Small Business Health Care Reform Efforts 2Health News:Pelosi Remarks at Press Availability with Easter Seals on Benefits of Health Reform for Children 2Health News:Pelosi Remarks at Press Availability with Easter Seals on Benefits of Health Reform for Children 3Health News:Stroke Treatment Window May Allow a Bit More Time 2Health News:New IVF Guidelines Aim to Reduce Multiple Births 2Health News:Paging All Science and Medical Mavens: Get To Philadelphia Stat for Body Worlds and Beyond 2Health News:Paging All Science and Medical Mavens: Get To Philadelphia Stat for Body Worlds and Beyond 3Health News:Paging All Science and Medical Mavens: Get To Philadelphia Stat for Body Worlds and Beyond 4Health News:Heart Failure Treatment Underused 2
... SG-2002 Stand-Alone Ganzfeld produces ... stimuli, which will elicit ... be amplified and recorded. ... is painted with a ...
... crescent-shaped interbody spacer used to provide anterior ... is available in either titanium or PEEK-OPTIMA, ... TraXis is implanted through a posterolateral approach ... and then curved across the midline to ...
... LKCs Sweep VEP technology is designed for productivity ... in conjunction with doctors from the University of ... over a decade on over 5,000 subjects. All ... be set and stored, or can be preset ...
... ALL-NEW CV-3000 Computerized Vision Tester offers ... and expands the many features of ... demand for delegating the refraction, electronic ... to generate an incredible interest in ...
Medicine Products: